Showing 831-840 of 5127 results for "".
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Moisturizer Effective in Acne Patients Using Topical Therapies: Analysishttps://practicaldermatology.com/news/moisturizer-boosts-skin-barrier-in-acne-patients-using-topical-therapies/2484743/New research showed a novel gel-matrix moisturizer improving skin barrier function and overall skin quality in adults with acne undergoing topical treatment. Researchers from Kenvue and Dermatology Consulting Services evaluated
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://practicaldermatology.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented